Actively Recruiting
Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke
Led by Xinqiao Hospital of Chongqing · Updated on 2025-12-26
800
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
Sponsors
X
Xinqiao Hospital of Chongqing
Lead Sponsor
Z
Zhejiang University
Collaborating Sponsor
AI-Summary
What this Trial Is About
In patients with acute ischemic stroke secondary to large vessel occlusion, the role of intravenous adjunctive medications, such as tirofiban, or alteplase before endovascular thrombectomy has not been well investigated. This trial aim to evaluate the efficacy and safety of intravenous tirofiban versus alteplase for acute ischemic stroke patients with large vessel occlusion piror to endovascular thrombectomy.
CONDITIONS
Official Title
Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Acute ischemic stroke symptoms
- Time from stroke onset to hospital arrival within 4.5 hours, or 4.5-9.0 hours meeting EXTEND trial imaging criteria, or over 4.5 hours but within 24 hours meeting WAKE-UP trial imaging criteria
- Eligible for intravenous thrombolysis
- Confirmed occlusion of internal carotid artery, M1 or M2 segment of middle cerebral artery, or vertebrobasilar artery by CTA, MRA, or DSA
- Informed consent obtained from patient or legal representative
You will not qualify if you...
- Evidence of brain hemorrhage on CT or MRI (micro-bleeds allowed)
- Contraindications to intravenous alteplase or tirofiban
- Contraindications to radiographic contrast agents, nickel, titanium metals, or their alloys
- Arterial tortuosity or other arterial conditions preventing device access to target vessel
- Preexisting neurological or psychiatric diseases that affect neurological assessments
- Evidence of mass effect or intracranial tumor on CT or MRI (except small meningioma)
- Evidence of cerebral vasculitis on CT or MRI
- Evidence of intracranial arteriovenous malformations or aneurysms on CTA or MRA
- Terminal illness with life expectancy less than 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
Research Team
H
Hongfei Sang, Doctor
CONTACT
Z
Zhongming Qiu, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here